Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.

被引：0
|
作者：
Karimi, Yasmin
Ghesquieres, Herve
Jurczak, Wojciech
Cheah, Chan
Clausen, Michael
Lugtenburg, Pieternella
Cunningham, David
Do, Young Rok
Lewis, David John
Gasiorowski, Robin
Kim, Tae Min
Van der Poel, Marjolein
Poon, Michelle Li Mei
Feldman, Tatyana A.
Linton, Kim M.
Sureda, Anna
Hutchings, Martin
Stirner, Mariana Cota
Sacchi, Mariana
Thieblemont, Catherine
机构：
[1] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI USA
[2] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France
[3] MSC Natl Res Inst Oncol, Krakow, Poland
[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia
[5] Vejle Hosp, Vejle, Denmark
[6] Univ Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands
[7] Royal Marsden NHS Fdn Trust, Sutton, England
[8] Keimyung Univ, Dongsan Med Ctr, Daegu, South Korea
[9] Univ Hosp Plymouth NHS Trust, Derriford Hosp, Plymouth, England
[10] Univ Sydney, Concord Hosp, Sydney, NSW, Australia
[11] Seoul Natl Univ Hosp, Seoul, South Korea
[12] Maastricht Univ, Med Ctr, Maastricht Dept Internal Med, Div Hematol GROW,Sch Oncol & Dev Biol, Maastricht, Netherlands
[13] Natl Univ Singapore Hosp, Singapore, Singapore
[14] Hackensack Univ, Hackensack Meridian Hlth, Med Ctr, Hackensack, NJ USA
[15] Christie NHS Fdn Trust, Manchester, England
[16] Manchester Canc Res Ctr, Manchester, England
[17] Univ Barcelona, Inst Catal Oncol, Hosp Duran & Reynals, IDIBELL,Hosp Llobregat, Barcelona, Spain
[18] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[19] AbbVie Inc, N Chicago, IL USA
[20] Genmab, Princeton, NJ USA
[21] Univ Paris, Hop St Louis, Assistance Publ & Hop Paris APHP, Hematooncol, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7525
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Subcutaneous Epcoritamab With R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated Results From EPCORE NHL-2
    Falchi, Lorenzo
    Clausen, Roost Michael
    Offner, Fritz
    de Vos, Sven
    Joshua, Brody D.
    Kim, Linton M.
    Snauwaert, Sylvia
    Cordoba, Raul
    Oki, Toshihiko
    Bykhovski, Irina
    Wang Liwei
    Rana, Ali
    Belada, David
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S50 - S50
  • [22] Characteristics of relapsed/refractory diffuse large B-cell lymphoma patients with durable responses to maveropepimut-S, pembrolizumab, and cyclophosphamide: Long-term follow-up from the SPiReL trial
    Pandey, Arjun
    Roos, Kim
    Jiang, Yidi
    Mangoff, Kathryn
    Klein, Gail
    Forward, Nick
    Stewart, Douglas
    Laneuville, Pierre
    Bence-Bruckler, Isabelle
    Mangel, Joy
    Tomlinson, George
    Berinstein, Neil L.
    EJHAEM, 2025, 6 (01):
  • [23] LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Kahl, Brad S.
    Hamadani, Mehdi
    Caimi, Paolo F.
    Carlo-Stella, Carmelo
    Ai, Weiyun
    Alderuccio, Juan Pablo
    Ardeshna, Kirit M.
    Hess, Brian
    Radford, John
    Solh, Melhem
    Stathis, Anastasios
    Feingold, Jay
    Ungar, David
    Qin, Yajuan
    He, Shui
    Zinzani, Pier Luigi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S377 - S378
  • [24] Glofitamab monotherapy in patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study
    Dietrich, S.
    Falchi, L.
    Carlo-Stella, C.
    Morschhauser, F.
    Hutchings, M.
    Bachy, E.
    Cartron, G.
    Khan, C.
    Tani, M.
    Martinez-Lopez, J.
    Bartlett, N.
    Salar, A.
    Brody, J.
    Leppa, S.
    Mulvihill, E.
    Lundberg, L.
    Relf, J.
    Xie, Y.
    Bottos, A.
    Humphrey, K.
    Dickinson, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 208 - 208
  • [25] Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE™ NHL-1 trial
    Soong, David
    Altintas, Isil
    Karavitis, John
    Linton, Kim M.
    Jurczak, Wojciech
    Thieblemont, Catherine
    Zhao, Kevin
    Szafer-Glusman, Edith
    Hoehn, Daniela
    Favaro, Elena
    Sacchi, Mariana
    Jure-Kunkel, Maria
    CANCER RESEARCH, 2024, 84 (06)
  • [26] Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
    Karimi, Yasmin H.
    Thieblemont, Catherine
    Ghesquieres, Herve
    Cheah, Chan Y.
    Clausen, Michael Roost
    Cunningham, David
    Jurczak, Wojciech
    Linton, Kim M.
    Hutchings, Martin
    Phillips, Tycel
    Farooq, Umar
    Kim, Won Seog
    Dinh, Minh H.
    Ghosh, Jagannath
    Pallai, Rajash
    Wielgos-Bonvallet, Monica
    Eskelund, Christian
    Lugtenburg, Pieternella J.
    Vose, Julie M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S461 - S462
  • [27] Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study
    Falchi, Lorenzo
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Hutchings, Martin
    Bachy, Emmanuel
    Cartron, Guillaume
    Khan, Cyrus
    Tani, Monica
    Martinez-Lopez, Joaquin
    Bartlett, Nancy L.
    Salar, Antonio
    Brody, Joshua
    Leppa, Sirpa
    Mulvihill, Estafania
    Lundberg, Linda
    Relf, James
    Xie, Yuying
    Bottos, Alessia
    Humphrey, Kathryn
    Dickinson, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Real-World Study of Polatuzumab Vedotin-Based Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Chinese Cohort: Updated Results of 2-Year Follow-up
    Wu, Jianqiu
    Li, Fei
    Wuxiao, Zhi-Jun
    Tang, Weiyan
    Teng, Yue
    Liu, Yanyan
    Chu, Han
    Wu, Zhiya
    Shen, Yiwen
    Kong, Fancong
    Yao, Zhihua
    Zhou, Weilun
    Feng, Jifeng
    BLOOD, 2023, 142
  • [29] Two-year follow-up result of RELIANCE study, a multicenter phase 2 trial of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma.
    Ying, Zhitao
    Song, Yuqin
    Yang, Haiyan
    Guo, Ye
    Li, Wenyu
    Zou, Dehui
    Zhou, Daobin
    Wang, Zhao
    Zhang, Mingzhi
    Wu, Jianqiu
    Liu, Hui
    Wang, Chris
    Yang, Su
    Zhou, Zisong
    Qin, Yun
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study
    Barba, Pere
    Lanar, Sally
    Liu, Fei Fei
    Eliason, Laurie
    Askew, Kshawna
    Devlen, Jennifer
    Furustrand, Ulrika
    Kostic, Ana
    BLOOD, 2023, 142
12345